Gleevec for systemic mastocytosis – pro

Gleevec is in a clinical study: Therapy of HES, PV, Atypical CML or CMML, and Mastocytosis With Imatinib Mesylate, NCT00038675. The goal of this clinical research study is to see if Gleevec, known as imatinib mesylate (STI571), can improve the disease condition in patients with hypereosinophilic syndrome (HES), polycythemia vera, atypical chronic myeloid leukemia (CML) or CMML with PDGF-R fusion genes, or mastocytosis.

There is significant supporting evidence. Gleevec may be useful in those types of systemic mastocytosis (systemic mast cell disease) that do not have mutations of the codon 816 on the c-kit gene and carry the wild-type kit. Imatinib mesylate may also be useful in a subtype of systemic mastocytosis that carries the FIP1L1-PDGFRA rearrangement.

Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. Nov 1 2003;102(9):3093-6

Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51

Participate in our Forums

To ask questions or participate in a discussion, please visit our Forums. You must LOGIN to participate.

Help Us Help Others

You can become a Site Sponsor. Or you may wish to support our work with a Donation.

Focused Articles For You

Lay Portal